Skip to main content

ICH Considerations General Principles to Address Virus and Vector Shedding (EMEA/CHMP/ICH/449035/2009)

 The document "GENERAL PRINCIPLES TO ADDRESS VIRUS AND VECTOR SHEDDING" (EMEA/CHMP/ICH/449035/2009) provides guidelines and principles for addressing the shedding of viruses and vectors in the context of gene therapy or other biotechnological products. Shedding refers to the release of these biological agents from the treated individual into the environment, potentially posing risks to others. Here's a summary of the general principles likely covered in this document:

Definition of Shedding:

The document likely provides a clear definition of what is meant by "shedding" in the context of gene therapy or biotechnological products. Shedding would involve the release of viral vectors or other genetic materials from the treated patient through various routes, such as body fluids, excreta, or skin lesions.

Risk Assessment:

The guidelines outline principles for conducting a comprehensive risk assessment related to shedding. This assessment would consider factors such as the type of vector or virus used, the route of administration, the potential for transmission, and the safety measures in place.

Monitoring and Detection:

It elaborate on how to monitor and detect shedding in patients receiving gene therapy or biotechnological products. This might involve surveillance of body fluids, secretions, or lesions and the use of sensitive assays for detecting viral or vector genetic material.

Communication and Reporting:

Principles for communication and reporting of shedding events are included. This also involve reporting to regulatory authorities, healthcare providers, and patients to ensure appropriate follow-up and safety measures.

Containment and Mitigation:

The document outline strategies for containing shedding and mitigating potential risks to others. This could include recommendations for patient isolation, safe handling of biological materials, and the use of personal protective equipment.

Patient Education:

It provide guidelines on educating patients about shedding risks and appropriate measures to take to prevent potential transmission to others.

Regulatory Compliance:

The document emphasizes the importance of regulatory compliance in addressing shedding concerns. This would include adhering to regulatory requirements and reporting any adverse events or shedding incidents as required by regulatory authorities.

Follow-Up and Long-Term Monitoring:

Guidelines for long-term follow-up and monitoring of patients who have undergone gene therapy or received biotechnological products may be provided. This is essential to assess the persistence of shedding and its potential long-term effects.

Overall, the document likely provides a framework for addressing the complex issue of virus and vector shedding in the context of gene therapy and biotechnological products, with a strong focus on patient safety and public health.

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more